DealForma Logo White
SCHEDULE A DEMO
SIGN IN
Top biopharma deal upfront October 2021

October 2021 Top Biopharma Deal: Xencor – Janssen for Plamotamab and XmAb Bispecific Antibodies

Nov 5, 2021 | Deal of the Month, Partnership Deals

October 2021 Top Biopharma Deal Upfront
Xencor development and commercialization deal with Janssen for plamotamab and XmAb bispecific antibodies

Highlighted Deal Financial Comps

Date Announced:

October 4, 2021

Total Deal Value:

$1,313M

Upfront Cash:

$100M

Upfront Equity:

$25M

Option Payments:

n/a

Total Milestones:

$1,188M (Dev., Reg., and Sales)

Royalties:

Tiered mid-teen to low-twenties

Cost & Profit Split:

n/a

Deal Synopsis

The Asset:

Phase I plamotamab, its CD20 x CD3 XmAb bispecific antibody as a monotherapy or in combination regimens, and new XmAb B-cell targeting bispecific antibodies for the treatment of CD20-expressing hematologic malignancies.

Deal Structure:

Development and Commercial License

Partnership Features:

Co-Development and co-promotion option to add compounds.

Deal Details:

  • Xencor granted Janssen exclusive, worldwide rights to develop and commercialize plamotamab, its CD20 x CD3 XmAb bispecific antibody as a monotherapy or in combination regimens, and new XmAb B-cell targeting bispecific antibodies for the treatment of CD20-expressing hematologic malignancies.
  • Janssen will pay 80% of costs and Xencor 20%.
  • Additionally, Xencor and Janssen signed a two-year research partnership to discover XmAb CD28 bispecific antibody applicants against B-cell targets by utilizing Xencor’s XmAb bispecific Fc technology while Janssen has an exclusive worldwide option to license and develop selected molecules in combination with plamotamab and other agents.
  • Xencor has the option to co-fund development costs in return for higher royalties and co-detailing rights for such products in the US.
  • Xencor will receive $100M in upfront cash, $25M in upfront equity investment, and is eligible for up to $1.19B in development, regulatory, and sales milestones, plus tiered mid-teen to low-twenties royalties.

Last Month:

Congrats to Xencor and Janssen for landing the DealForma October 2021 Deal of the Month. The Deal of the Month for September 2021 was REGENXBIO and AbbVie’s deal with $370M up front for RGX-314. Read about it here.

DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.

We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.

21,135

Licensing Deals

21,479

Funding Rounds

4,145

M&A

34,717

Company Profiles

5,766

Other Deals

26,805

Drug Sales Figures

All of this by stage, disease indication, modality, target...

Schedule Your Demo

More Research by DealForma

Neurology Venture Activity Through Q2 2023

Neurology Venture Activity Through Q2 2023

Sep 15, 2023 |

Quarterly venture investment activity into neurology focused biopharma companies is back to pre-2020 level. This is no surprise given the investment slowdowns across all therapy area and broader life sciences. The drop seems to have stabilized however, and emerging...